| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Paeoniflorigenone targets multiple cellular pathways involved in cancer progression and neuromuscular function. It induces apoptosis selectively in cancer cell lines through mechanisms involving caspase activation and DNA fragmentation. The compound exhibits antiproliferative effects by inhibiting tumor cell proliferation. As a depolarizing neuromuscular blocking agent similar to succinylcholine, paeoniflorigenone may interact with nicotinic acetylcholine receptors at the neuromuscular junction. Both Paeoniae Radix and Moutan Cortex, from which paeoniflorigenone is derived, have been used as remedies for cardiovascular diseases and for improving blood circulation. The compound's selective activity against tumor cells while sparing normal cells suggests specificity in its mechanism of action.
|
|---|---|
| ln Vitro |
Paeoniflorigenone (0–30 μM; 0-72 hours) dramatically reduces tumor cell line proliferation while inhibiting normal cell line proliferation[1]. Selective apoptotic DNA fragmentation in tumor cells is significantly induced by pheoniflorigenone (0-30 μM) over a 24-72-hour period[1].
In vitro, paeoniflorigenone (0-30 µM; 24-72 hours) significantly reduces tumor cell line proliferation while having less effect on normal cell lines. The compound significantly induces apoptotic DNA fragmentation selectively in tumor cells. Paeoniflorigenone has been shown to induce DNA fragmentation in three tumor cell lines (TIG-1, 3T3-L1, HL60, Jurkat, and HeLa cells) but not in two normal cell lines. This selective induction of apoptosis in cancer cells is a key feature of its anticancer activity. The compound's antiproliferative effect is dose- and time-dependent, with increasing inhibition observed at higher concentrations and longer incubation times. Its activity as a depolarizing neuromuscular blocking agent has also been characterized in vitro. |
| ln Vivo |
In vivo, paeoniflorigenone's biological activities have been studied primarily in the context of its traditional use in Paeonia species for cardiovascular diseases and blood circulation improvement. The compound's selective induction of apoptosis in tumor cells suggests potential anticancer activity that could be explored in animal tumor models. However, detailed in vivo efficacy and safety data are limited. The compound's neuromuscular blocking activity may have implications for its effects on motor function. Further research is needed to fully characterize its in vivo biological activity, therapeutic potential, and safety profile. Researchers should consult the primary literature for available in vivo data.
|
| Enzyme Assay |
For in vitro biochemical assays, paeoniflorigenone is evaluated for its effects on apoptosis and cell proliferation. Apoptosis induction is assessed by measuring caspase 3/7 activity using fluorogenic substrates, DNA fragmentation using gel electrophoresis or TUNEL assays, and phosphatidylserine exposure using Annexin V binding. Cell proliferation is measured using MTT, SRB, or BrdU incorporation assays. Neuromuscular blocking activity can be assessed using isolated nerve-muscle preparations or by measuring effects on acetylcholine receptor function. Receptor binding assays can be performed to assess interactions with nicotinic acetylcholine receptors. These cell-free and cell-based assays help characterize the compound's pro-apoptotic, antiproliferative, and neuromuscular activities.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: TIG-1, 3T3-L1, HL60, Jurkat and HeLa cells Tested Concentrations: 0-30 μM Incubation Duration: 0-72 hrs (hours) Experimental Results: Dramatically diminished the cell proliferation of tumor cell lines and inhibited the proliferation of normal cell lines. Apoptosis Analysis[1] Cell Types: TIG-1 and 3T3-L1 (normal cells), HL60, Jurkat, and HeLa cells (tumor cells) Tested Concentrations: 0, 1, 3, 10, 30 μM Incubation Duration: 24 and 72 hrs (hours) Experimental Results: Induced DNA fragmentation in three tumor cell lines, but not in two normal cell lines. In vitro cellular assays for paeoniflorigenone are performed using various cancer cell lines including TIG-1, 3T3-L1, HL60, Jurkat, and HeLa cells, as well as normal cell lines for comparison. Cells are cultured in standard media and treated with paeoniflorigenone at concentrations ranging from 0 to 30 µM for 24-72 hours. Cell viability and proliferation are assessed using MTT, SRB, or colony formation assays. Apoptosis is evaluated by measuring caspase activity, DNA fragmentation, and Annexin V/PI staining. Cell cycle analysis is performed using propidium iodide staining and flow cytometry. The selectivity index is calculated by comparing effects on tumor cells versus normal cells. These cellular assays help validate the compound's selective anticancer activity and characterize its mechanism of action. |
| Animal Protocol |
In vivo animal experiments with paeoniflorigenone are not extensively documented in the literature. As a compound derived from Paeonia species used traditionally for cardiovascular diseases, animal models of cardiovascular disease could be used to study its effects on blood circulation and cardiac function. For anticancer studies, tumor xenograft models could be employed to evaluate the compound's in vivo efficacy. Paeoniflorigenone would be administered via oral gavage, intraperitoneal injection, or intravenous injection at doses determined from pharmacokinetic and tolerability studies. Efficacy endpoints would include tumor growth inhibition, apoptosis induction in tumor tissues, and survival. Neuromuscular effects could be assessed using motor function tests. Researchers should consult the primary literature for any available in vivo protocols and data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of paeoniflorigenone are not extensively documented. As a monoterpene compound with moderate lipophilicity (molecular weight 318.325, C17H18O6), it is expected to have moderate oral bioavailability and good tissue distribution. The compound's ability to induce apoptosis and exert neuromuscular blocking effects suggests that it can reach target tissues including tumors and neuromuscular junctions. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, volume of distribution, and clearance are not available in the literature. Researchers should consult the primary literature for any available pharmacokinetic data. The compound's stability and formulation requirements would need to be optimized for in vivo studies.
|
| Toxicity/Toxicokinetics |
The toxicological profile of paeoniflorigenone is not extensively characterized. The compound's selective induction of apoptosis in tumor cells while sparing normal cells suggests a favorable safety profile. However, its neuromuscular blocking activity could cause toxicity at high doses, potentially affecting respiratory function and motor control. As a compound derived from Paeonia species used traditionally, it may have a history of safe use in traditional medicine, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications without appropriate safety evaluation. Researchers should follow standard laboratory safety practices when handling paeoniflorigenone.
|
| References | |
| Additional Infomation |
There have been reports that peony (Paeonia rockii) contains paeoniflorin, and relevant data are available for reference.
Paeoniflorigenone is a valuable research tool for studying selective apoptosis induction in cancer cells and neuromuscular function. Its ability to selectively induce apoptosis in tumor cells while sparing normal cells makes it useful for investigating the molecular mechanisms of cancer cell selectivity and developing targeted anticancer strategies. The compound's neuromuscular blocking activity provides opportunities for studying neuromuscular transmission and developing neuromuscular blocking agents. Its origin from Paeonia species used in traditional medicine makes it relevant for natural product chemistry and ethnopharmacology research. Paeoniflorigenone can be employed to study the mechanisms of action of Paeonia-derived compounds and their potential therapeutic applications in cancer and cardiovascular diseases. |
| Molecular Formula |
C17H18O6
|
|---|---|
| Molecular Weight |
318.32
|
| Exact Mass |
318.11
|
| CAS # |
80454-42-8
|
| PubChem CID |
133475
|
| Appearance |
White to off-white ointment
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
481.1±45.0 °C at 760 mmHg
|
| Flash Point |
177.1±22.2 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
2.87
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C([C@@H]1[C@@H]2C(C[C@]3([C@](C2)(O)O[C@@H]1O3)C)=O)OC(C1C=CC=CC=1)=O
|
| InChi Key |
BANPEMKDTXIFRE-GMKCAIKYSA-N
|
| InChi Code |
InChI=1S/C17H18O6/c1-16-8-13(18)11-7-17(16,20)23-15(22-16)12(11)9-21-14(19)10-5-3-2-4-6-10/h2-6,11-12,15,20H,7-9H2,1H3/t11-,12+,15-,16+,17-/m0/s1
|
| Chemical Name |
[(1S,3R,6S,8S,10S)-8-hydroxy-3-methyl-5-oxo-2,9-dioxatricyclo[4.3.1.03,8]decan-10-yl]methyl benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1415 mL | 15.7075 mL | 31.4149 mL | |
| 5 mM | 0.6283 mL | 3.1415 mL | 6.2830 mL | |
| 10 mM | 0.3141 mL | 1.5707 mL | 3.1415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
